Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Vanderbilt investigators isolate human antibodies against H7 bird flu

Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

10 Mar 2016

Thermo Fisher exhibits new UHPLC-MS workflow solutions for biopharmaceutical characterization at Pittcon 2016

Biopharmaceutical companies can now achieve advanced levels of specificity, sensitivity and speed with specialized analytical workflow solutions for the characterization and quantification of proteins.

From Thermo Fisher Scientific Inc. 9 Mar 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C.

8 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

Aflibercept (trade name: Eylea) has been approved since October 2015 for adults with impaired vision due to myopic choroidal neovascularisation.

2 Mar 2016

Single antibody could hold promise as potential treatment for human cases of EVD

A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today's online edition of the journal Science.

27 Feb 2016

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

The Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, and Humabs BioMed SA, a Swiss antibody therapeutics company, have identified, isolated and characterized two Ebola virus neutralizing monoclonal antibodies from the blood of a survivor of an Ebola infection.

27 Feb 2016

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).

27 Feb 2016

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy.

26 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Antibody can give more precise information about Alzheimer's disease than regular radioactive tracers

For the first time, researchers have succeeded in passing an antibody through the blood-brain barrier to act as a tracer for PET imaging of the brain. This resulted in more precise information being obtained than with regular radioactive tracers. The study provides hope for more effective diagnosis of early onset Alzheimer's disease and improvements in monitoring the effects of medication.

22 Feb 2016

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

More phase II success for CGRP migraine prevention strategy

Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.

18 Feb 2016

Corvidia Therapeutics secures $26 million in Series A financing

Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

18 Feb 2016

Aytu BioScience announces business strategy update and Q2 financial results

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended December 31, 2015.

17 Feb 2016

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

A first-ever interlaboratory study of four versions of a therapeutic protein drug—all manufactured from living cells—reports that an established analytical tool akin to magnetic resonance imaging reliably assessed the atomic structures of the biologically similar products, yielding the equivalent of a fingerprint for each.

10 Feb 2016

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic's proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions.

8 Feb 2016

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

1 Feb 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

UI researchers uncover how cancer cells form tumors

Two University of Iowa studies offer key insights by recording in real time, and in 3-D, the movements of cancerous human breast tissue cells. It's believed to be the first time cancer cells' motion and accretion into tumors has been continuously tracked.

27 Jan 2016

Monoclonal Antibody News and Research

Further Reading

Vanderbilt investigators isolate human antibodies against H7 bird flu

Thermo Fisher exhibits new UHPLC-MS workflow solutions for biopharmaceutical characterization at Pittcon 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

Single antibody could hold promise as potential treatment for human cases of EVD

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Antibody can give more precise information about Alzheimer's disease than regular radioactive tracers

Researchers identify new group of powerful Ebola-fighting antibodies

More phase II success for CGRP migraine prevention strategy

Corvidia Therapeutics secures $26 million in Series A financing

Aytu BioScience announces business strategy update and Q2 financial results

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

UI researchers uncover how cancer cells form tumors

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®